<DOC>
	<DOCNO>NCT02949999</DOCNO>
	<brief_summary>The study single-centre , double-blind , placebo control , randomize , ascend multiple dose study ass safety , tolerability , pharmacokinetics pharmacodynamic profile voclosporin .</brief_summary>
	<brief_title>Voclosporin Healthy Japanese Volunteers</brief_title>
	<detailed_description>Ten subject randomize four treatment group receive approximately 0.25 , 0.5 , 1.0 , 1.5mg/kg/dose voclosporin v placebo . For Day 1 , subject give oral treatment day ; Day 2 , subject give oral treatment ; Day 3-12 , subject give oral treatment twice day ; Day 13 , subject give oral treatment day . The duration study take 21 day ( include follow assessment ) .</detailed_description>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Key Japanese male female birth age 20 45 year inclusive Females nonpregnant , nonlactating , either postmenopausal least 1 year , surgically sterile least 3 month , 35 day prior study entry ( i.e . Day 2 ) 30 day follow study completion/discharge use approve method contraception . Males sterile time dose administration 30 day follow dose administration use approve method contraception . Screening FSH &gt; 40 IU/ml selfidentified postmenopausal female subject . Weight must &gt; 55 kg &lt; 100 kg , BMI 1830 kg/m2 inclusive . Healthy define normal screening assessment , include full medical history , complete physical examination , vital sign , 12lead ECG , hematology , blood chemistry urinalysis . Laboratory result must within reference range consider clinically significant Principal Investigator agreement Medical Monitor . Lab test may repeat screen period appropriate . Capable participate , provide informed consent comply study procedure restriction Must agree refrain consumption grapefruit juice least one week prior dose followup procedure complete . Key History drug abuse and/or alcoholism previous 2 year . Positive urine drug test , urine cotinine test alcohol breath test screening . Positive Hepatitis B , Hepatitis C HIV . QTcB &gt; 430 msec male , QTcB &gt; 450 msec female 12lead ECG trace screen . Blood donation within 56 day prior dose plasma donation within 7 day prior first dosing . Hemoglobin value &lt; 12 g/dL . Current smoker ( smoke cigarette form tobacco nicotine use must stop least 90 day screen ) . History alcohol consumption average 2 drink per day week ( 1 drink 12 oz beer , 4 oz wine 1.5oz spirit ) within 6 month prior screen . Alcoholcontaining food beverage prohibit within 7 day prior study entry entire study duration . Use drug know inhibit induce hepatic drug metabolism ( i.e . inducer include barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; inhibitor include antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) within 30 day prior administration study medication . Participation clinical trial involve administration investigational market drug within 30 day ( 90 day biologics ) prior first dosing Use prescription medication within 14 day prior first dose overthecounter product ( include natural product , vitamin , garlic supplement ) within 7 day prior first dosing , except topical product without systemic absorption , likely need medication study period . Clinically significant abnormal liver function , abnormal renal function , active tuberculosis ( TB ) , know history TB/evidence old TB take prophylaxis isoniazid , current recent infection , history hypertension history malignancy . Any reason , opinion Principal Investigator Sponsor 's medical monitor , would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Calcineurin inhibitor</keyword>
	<keyword>Voclosporin</keyword>
</DOC>